Welcome
Support Centre
11 February 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
The effect of PRIME-MD on the detection and referral-for-treatment of occult psychiatric treatment in the Emergency Department (ED).
ISRCTN ISRCTN61514736
ClinicalTrials.gov identifier
Public title The effect of PRIME-MD on the detection and referral-for-treatment of occult psychiatric treatment in the Emergency Department (ED).
Scientific title
Acronym UCLA PRIME MD-2
Serial number at source N/A
Study hypothesis Not provided at time of registration.
Lay summary
Ethics approval Not provided at time of registration.
Study design Randomised controlled trial
Countries of recruitment United States of America
Disease/condition/study domain Depression, anxiety and other psychiatric conditions
Participants - inclusion criteria ED patients who present with a somatic (non-psychiatric) complaint that is of long duration, is chronic, or is not of a severity to warrant emergency care.
Resident physicians in Emergency Medicine and their faculty.
Participants - exclusion criteria Not provided at time of registration.
Anticipated start date 01/03/2002
Anticipated end date 01/09/2002
Status of trial Completed
Patient information material
Target number of participants Not provided at time of registration.
Interventions Patients take the computerized PRIME-MD in the ED waiting room. They are randomized to three groups: PRIME-MD results shared with no one, shared with the patient only, or shared with the patient and the treating ED physician.
Low cost/no cost psychiatric referral sheet made available in the ED.
Primary outcome measure(s) Not provided at time of registration.
Secondary outcome measure(s) Not provided at time of registration.
Sources of funding The Pfizer Corporation provided a $60,000 gift (not grant) in support of this research.
Trial website
Publications Results in: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15882462
Contact name Dr  David  Schriger
  Address 924 Westwood Blvd Suite 300
  City/town Los Angeles, CA
  Zip/Postcode 90024-2924
  Country United States of America
  Tel +1 310 794 0593
  Email schriger@ucla.edu
Sponsor University of California, Los Angeles (UCLA) (USA)
  Address 924 Westwood Blvd Suite 300
  City/town Los Angeles, CA
  Zip/Postcode 90024 2924
  Country United States of America
Date applied 17/02/2005
Last edited 03/08/2007
Date ISRCTN assigned 21/02/2005
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central